Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis Thu H. N. NguyenThanh T. N. NguyenHue T. Nguyen Review 09 September 2022 Pages: 1 - 15
Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments Rosa-Maria FerraiuoloBre-Anne FifieldLisa A. Porter Preclinical study 27 August 2022 Pages: 17 - 30
USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells Yang SuChenming WuJian Yuan Preclinical study 30 August 2022 Pages: 31 - 44
STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression Yuan-Ming SongXiao-Long QianXiao-Jing Guo Preclinical study 03 September 2022 Pages: 45 - 56
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform Frederick M. HowardGong HeRita Nanda Preclinical study Open access 05 September 2022 Pages: 57 - 66
Survival outcomes for breast conserving surgery versus mastectomy among elderly women with breast cancer Weimin XieMin CaoZicheng Li Preclinical study 07 September 2022 Pages: 67 - 74
Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients Constantin SajdikEva SchusterEva Obermayr Preclinical study Open access 08 September 2022 Pages: 75 - 85
Highly specialized Breast Centers did not experience delay of care during COVID-19 pandemic in Italy: the Senonetwork experience Agnese LosurdoAndrea Vittorio Emanuele LisaThe Senonetwork Working Group Clinical trial 26 August 2022 Pages: 87 - 95
Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe? Fei-Lin QuCai-Jin LinZhi-Ming Shao Clinical trial Open access 30 August 2022 Pages: 97 - 109
Increased EAT volume after anthracycline chemotherapy is associated with a low risk of cardiotoxicity in breast cancer Seong Soon KwonBo Da NamSoon Hyo Kwon Clinical trial 31 August 2022 Pages: 111 - 119
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy Song Yi ParkKoung Jin SuhSeock-Ah Im Clinical trial 07 September 2022 Pages: 121 - 128
Axilla lymph node dissection can be safely omitted in patients with 1–2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis Weiqi GaoShuangshuang LuKunwei Shen Clinical trial 08 September 2022 Pages: 129 - 141
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers Maryam Nemati ShafaeeKristina GoutsouliakBanu Arun Epidemiology 25 August 2022 Pages: 143 - 152
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer Danielle M. FileTomas PascualLisa A. Carey Epidemiology 25 August 2022 Pages: 153 - 162
Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer Kristen D. WhitakerXiaoliang WangLori J. Goldstein Epidemiology Open access 26 August 2022 Pages: 163 - 173
Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer Tanya GuptaNatasha PuringtonAllison W. Kurian Epidemiology 28 August 2022 Pages: 175 - 183
Postmenopausal overweight and breast cancer risk; results from the KARMA cohort Marie KlintmanAnn H. RosendahlSigne Borgquist Epidemiology Open access 30 August 2022 Pages: 185 - 196
Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study Christina M. S. HassingMathias Kvist MejdahlTove Holst Filtenborg Tvedskov Epidemiology 08 September 2022 Pages: 197 - 206
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience Julia LevyFady FaragJohn Cole Epidemiology Open access 09 September 2022 Pages: 207 - 213
Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions Claire E. P. SmithPaul K. MarcomNaomi Y. Ko Epidemiology 10 September 2022 Pages: 215 - 220
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer Mariya RozenblitKim BlenmanLajos Pusztai Brief Communication 26 August 2022 Pages: 221 - 227
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study Grace M. ChoongSavannah LiddellKarthik V. Giridhar Brief Communication 31 August 2022 Pages: 229 - 237
Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: correspondence Rujittika MungmunpuntipanjtipWon SriwijitalaiViroj Wiwanitkit Letter to the Editor 31 August 2022 Pages: 239 - 239
Strict definition of a small tumor in breast cancer should be revisited Ahmet Necati SanliKadri Altundag Letter to the Editor 02 September 2022 Pages: 241 - 241
De-escalation of breast cancer treatment for Her2-positive breast cancer Parinita SwarnkarLara MokbelKefah Mokbel Letter to the Editor 09 September 2022 Pages: 243 - 244